ArticleNeuro-oncology advances
Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma.
Eugene J Vaios et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
pooled itcites it